+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study



Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study



Journal of Gastrointestinal and Liver Diseases 19(4): 387-392



The role of nitric oxide (NO) in infectious diseases is gaining attention because of its antiviral effects. To evaluate whether serum and hepatic NO levels are predictors of the outcome of treatment in patients with chronic hepatitis C genotype 4. Fifty six patients with chronic HCV genotype 4 treated with pegylated interferon (IFN) alpha-2a plus ribavirin underwent blood tests, assessment of serum level of NO and hepatic tissue expression of NO synthase (iNOS) before and during treatment. The pre-treatment serum NO level was significantly higher in sustained responders (SR) [39.583 (35-43.8)] compared to relapsers [36.25 (26-43.8)], and non responders (NR) [35.417 (25.0-43.8)]. During treatment, the serum NO level was significantly higher in SR [58.125 (47.9-60.6)] compared to relapsers [53.854 (47.9-59.4)] and NR [50 (42.9-59.4)]. The pre-treatment iNOS expression was significantly higher in SR [37.5 (15-75)] compared with either relapsers [25 (15-45)] and or NR [20 (2-45)]. In multivariate logistic regression analysis, the serum NO was correlated with the virological response to pegylated interferon alpha-2a plus ribavirin therapy. In patients with chronic hepatitis C, nitric oxide levels may be associated with the outcome of pegylated-IFN-α 2a plus ribavirin treatment.

(PDF emailed within 1 workday: $29.90)

Accession: 054626422

Download citation: RISBibTeXText

PMID: 21188329


Related references

Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver International 29(2): 248-252, 2008

Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scandinavian Journal of Gastroenterology 45(2): 250-255, 2010

Sustained virological response of pegylated interferon alpha-2A plus ribavirin in patients with chronic hepatitis C genotype 4. Gut 53(Suppl 3): A81, April, 2004

IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C. Plos One 10(4): E0121395, 2016

Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. Journal of Interferon and Cytokine Research 35(1): 49-54, 2015

Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. Digestive Diseases and Sciences 56(8): 2449-2455, 2011

Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis. Excli Journal 12: 605-615, 2013

Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatology Research 40(2): 135-144, 2009

Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis. Digestion 79(1): 36-39, 2009

Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C. Alimentary Pharmacology and Therapeutics 30(5): 487-494, 2010

Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin. Kaohsiung Journal of Medical Sciences 32(7): 381-386, 2017

High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. Hepatology International 9(1): 76-83, 2016

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Annals of Saudi Medicine 29(1): 4-14, 2009

A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin. Memorias do Instituto Oswaldo Cruz 107(7): 888-892, 2013

Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology 52(5): 247-251, 2009